MedKoo Cat#: 564774 | Name: FLLL12

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FLLL12, also known as GO-Y 026, is a Curcumin analogue which exhibits enhanced growth-suppressive activity and inhibits AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. FLLL12 is significantly more potent and has more favorable pharmacokinetic properties than curcumin. FLLL12 strongly inhibited the expression of p-EGFR, EGFR, p-AKT, AKT, Bcl-2, and Bid and increased the expression of Bim. Overexpression of constitutively active AKT or Bcl-2 or ablation of Bim or Bid significantly inhibited FLLL12-induced apoptosis. Further mechanistic studies revealed that FLLL12 regulated EGFR and AKT at transcriptional levels, whereas Bcl-2 was regulated at the translational level. Finally, FLLL12 strongly inhibited the AKT downstream targets mTOR and FOXO1a and 3a.

Chemical Structure

FLLL12
FLLL12
CAS#917813-60-6

Theoretical Analysis

MedKoo Cat#: 564774

Name: FLLL12

CAS#: 917813-60-6

Chemical Formula: C21H22O7

Exact Mass: 386.1366

Molecular Weight: 386.40

Elemental Analysis: C, 65.28; H, 5.74; O, 28.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
FLLL-12; FLLL 12; FLLL12; GO-Y 026; GO-Y-026; GO-Y026;
IUPAC/Chemical Name
1,5-Bis-(4-hydroxy-3,5-dimethoxy-phenyl)-penta-1,4-dien-3-one
InChi Key
DDGVRFAFSCAHHH-KQQUZDAGSA-N
InChi Code
InChI=1S/C21H22O7/c1-25-16-9-13(10-17(26-2)20(16)23)5-7-15(22)8-6-14-11-18(27-3)21(24)19(12-14)28-4/h5-12,23-24H,1-4H3/b7-5+,8-6+
SMILES Code
O=C(/C=C/C1=CC(OC)=C(O)C(OC)=C1)/C=C/C2=CC(OC)=C(O)C(OC)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
FLLL12 is a potent curcumin analogue with more favorable pharmacokinetic properties that induces apoptosis of head and neck cancer cell lines by inhibition of survival proteins including EGFR, AKT, and Bcl-2 and increasing of the proapoptotic protein Bim.

Preparing Stock Solutions

The following data is based on the product molecular weight 386.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Haque A, Rahman MA, Fuchs JR, Chen Z, Khuri FR, Shin DM, Amin ARMR. Corrigendum to "FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway" [Canc. Lett. 363 (2015) 166-175]. Cancer Lett. 2021 Feb 1;498:249-250. doi: 10.1016/j.canlet.2020.07.039. Epub 2020 Oct 20. Erratum for: Cancer Lett. 2015 Jul 28;363(2):166-75. PMID: 33092912. 2: Anisuzzaman AS, Haque A, Rahman MA, Wang D, Fuchs JR, Hurwitz S, Liu Y, Sica G, Khuri FR, Chen ZG, Shin DM, Amin AR. Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. Cancer Prev Res (Phila). 2016 Jan;9(1):63-73. doi: 10.1158/1940-6207.CAPR-15-0240. Epub 2015 Oct 28. PMID: 26511491; PMCID: PMC4706799. 3: Haque A, Rahman MA, Fuchs JR, Chen ZG, Khuri FR, Shin DM, Amin AR. FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway. Cancer Lett. 2015 Jul 28;363(2):166-75. doi: 10.1016/j.canlet.2015.04.017. Epub 2015 Apr 24. Erratum in: Cancer Lett. 2021 Feb 1;498:249-250. PMID: 25917567; PMCID: PMC4433807. 4: Lin L, Hutzen B, Ball S, Foust E, Sobo M, Deangelis S, Pandit B, Friedman L, Li C, Li PK, Fuchs J, Lin J. New curcumin analogues exhibit enhanced growth- suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci. 2009 Sep;100(9):1719-27. doi: 10.1111/j.1349-7006.2009.01220.x. Epub 2009 May 18. PMID: 19558577. 5: Friedman L, Lin L, Ball S, Bekaii-Saab T, Fuchs J, Li PK, Li C, Lin J. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anticancer Drugs. 2009 Jul;20(6):444-9. doi: 10.1097/CAD.0b013e32832afc04. PMID: 19384191; PMCID: PMC2855307. 6: Cen L, Hutzen B, Ball S, DeAngelis S, Chen CL, Fuchs JR, Li C, Li PK, Lin J. New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells. BMC Cancer. 2009 Mar 30;9:99. doi: 10.1186/1471-2407-9-99. PMID: 19331692; PMCID: PMC2674881.